Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Teva
Israel - Petach Tikva
DALBAVANCIN HYDROCHLORIDE (dalbavancin) by Teva is [see microbiology ( )] . Approved for skin structure infections (absssi) caused by designated susceptible strains of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-susceptible, methicillin-resistant isolates), streptococcus pyogenes and 3 more indications. First approved in 2025.
Drug data last refreshed 20h ago
[see Microbiology ( )] .
Worked on DALBAVANCIN HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
Evaluation of Intravenous Dalbavancin for Peritonitis
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo